[DOI] [PubMed] [Google Scholar] 140.Ashdown-Franks G., Firth J., Carney R., Carvalho A.F., Hallgren M., Koyanagi A., Rosenbaum S., Schuch F.B., Smith L., Solmi M., et al
For many of our patients, the good far outweighs the bad when it comes to GLP-1 agonists, and theyre thrilled to finally get the upper hand when it comes to their weight
Protein binding is saturable: it decreases with increasing valproate concentration, low albumin concentrations, the patient's age, additional use of other drugs such as aspirin, as well as liver and kidney impairment
These side effects have been reported in approximately 2040% of people and are most common during dose initiation and escalation